Biotech entity
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention DaVita, the most common co-covered peer. We currently track 1 Biotech story that mention Ocular Therapeutix, all published on June 22, 2026.
Last mentioned: Jun 22, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, gene-therapy. Of the tracked stories, 1 of 1 also mention DaVita, the most common co-covered peer. We currently track 1 Biotech story that mention Ocular Therapeutix, all published on June 22, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Ocular Therapeutix. Shared-story counts are live from our verified record — not editorial picks.
Ocular Therapeutix's commercial revenues are shrinking amid massive losses, while Prime Medicine's Prime Editing platform promises a DNA cure but lacks any product revenue. Both illustrate the extreme risk-reward calculus of biotech investing, where a single clinical win can eclipse years of cash burn.
Source: Pamela Kock (us) · Pamela Kock (us)
Ocular Therapeutix is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
